aHSCT Beneficial for Most Patients With Relapsing-Remitting MS

TUESDAY, Sept. 26, 2023 -- Autologous hematopoietic stem cell transplantation (aHSCT) for treatment of relapsing-remitting multiple sclerosis (RRMS) yields freedom from disease activity for most patients, according to a study published online Sept....
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news